What is HC Wainwright’s Estimate for BRNS Q3 Earnings?

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) – Research analysts at HC Wainwright issued their Q3 2026 earnings estimates for shares of Barinthus Biotherapeutics in a report released on Tuesday, August 25th. HC Wainwright analyst Y. Chen forecasts that the company will post earnings per share of ($0.27) for the quarter. HC Wainwright also issued estimates for Barinthus Biotherapeutics’ Q4 2026 earnings at ($0.27) EPS and FY2026 earnings at ($0.93) EPS.

Separately, Weiss Ratings upgraded Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $4.00.

Barinthus Biotherapeutics Price Performance

NASDAQ:BRNS opened at $0.71 on Thursday. The business’s 50-day moving average is $0.62 and its two-hundred day moving average is $0.63. The firm has a market capitalization of $28.86 million, a PE ratio of -0.69 and a beta of -0.39. Barinthus Biotherapeutics has a 12 month low of $0.51 and a 12 month high of $1.83.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02.

Institutional Investors Weigh In On Barinthus Biotherapeutics

A number of large investors have recently added to or reduced their stakes in the company. Baird Financial Group Inc. lifted its holdings in Barinthus Biotherapeutics by 108.2% in the 2nd quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock worth $179,000 after buying an additional 100,000 shares in the last quarter. Rangeley Capital LLC grew its stake in shares of Barinthus Biotherapeutics by 88.8% during the first quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock valued at $91,000 after acquiring an additional 75,024 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Barinthus Biotherapeutics by 115.8% during the fourth quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock worth $100,000 after acquiring an additional 76,800 shares during the last quarter. 25.20% of the stock is owned by institutional investors and hedge funds.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.